INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.630
0.00 (0.00%)
At close: Nov 7, 2025, 4:00 PM EST
1.650
+0.020 (1.23%)
After-hours: Nov 7, 2025, 7:55 PM EST
INmune Bio Revenue
INmune Bio had revenue of $50.00K in the twelve months ending September 30, 2025, up 19.05% year-over-year. In the year 2024, INmune Bio had annual revenue of $14.00K, down -90.97%.
Revenue (ttm)
$50.00K
Revenue Growth
+19.05%
P/S Ratio
866.68
Revenue / Employee
$2,273
Employees
22
Market Cap
43.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
| Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
| Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
| Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
| Dec 31, 2020 | 11.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INMB News
- 8 days ago - INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update - GlobeNewsWire
- 25 days ago - INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 - GlobeNewsWire
- 3 months ago - INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment - GlobeNewsWire
- 3 months ago - INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th - GlobeNewsWire
- 3 months ago - INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference - GlobeNewsWire
- 4 months ago - INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's - Seeking Alpha